Egham, UK – 21 June, 2022 – Essential Pharma, an international specialty pharma group focused on maintaining access to well-established, “at risk” products essential to patients across multiple therapeutic areas, announces the appointment of Soren Demin as the new Global Vice-President of Commercial and Head of Business Development.
“We’re delighted to welcome Soren to the team and look forward to benefitting from his vast knowledge of pharmaceutical business development as we expand our operations to ensure the long-term supply of essential medicines in both new and existing global markets,” commented Steen Vansgaard, Chief Executive Officer of Essential Pharma. “Soren has a successful record of fostering biopharmaceutical partnerships as well as specialist banking and financial experience, which will be critical in supporting our company’s vision and sustainable growth strategy.”
Soren has close to 15 years of global biopharmaceutical experience in both commercial and business development. He joins Essential Pharma from Porton BioPharma where, as a Director, he had responsibility for establishing new strategic collaborations and overseeing the development and manufacturing of various therapeutic products. Prior to this, Soren worked at Mitsubishi Tanabe Pharma Corporation in Business Development where he was responsible for driving major growth opportunities and the successful execution of in-licence agreements. Soren studied for his undergraduate degree in Sheffield and his post graduate qualifications from the University of Cambridge
“I am thrilled to join Essential Pharma’s dynamic team as the company pursues its ambitious growth plans to provide a broader range of “at risk” treatments to an increasing number of patients globally,” added Soren Demin. “I look forward to building upon the company’s strong portfolio and expanding and establishing new pharmaceutical collaborations that are a vital element of Essential Pharma’s growth strategy.”